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Study importance questions 
 
What major reviews have been published 
• In a major review in JAMA Pediatrics (Harskamp-van Ginkel et al., 2015), 
coverage was exclusively drug disposition studies published through 2012, 
yielding mostly uncommon drugs with pediatric data. Another pediatric paper 
(Kyler et al., 2019) reviewed 23 drugs frequently prescribed to pediatric 
inpatients. 
• Other journal reviews were similarly limited in scope to pharmacokinetics and/or 
one therapeutic category, i.e., antibiotics, or clinical setting, i.e., surgery or 
emergency medicine.  
 
What this review adds 
• Our up-to-date literature review provides a critical appraisal of pediatric obesity 
clinical research, covering 70 medications in common use among hospitalized 
pediatric patients in the U.S.  
• This overview identifies trends and knowledge gaps which will help prioritize 
research direction to focus on areas of greatest clinical need.  
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Abstract  
 
Medication management in children and adolescents with obesity is challenging since 
both developmental and pathophysiologic changes may impact drug disposition and 
response. Evidence to date indicates an effect of obesity on drug disposition for certain 
drugs used in this population. This work identified published studies evaluating drug 
dosing, pharmacokinetics, and effect in pediatric patients with obesity, focusing on 70 
common medications used in a pediatric network of 42 U.S. medical centers.  
A PubMed search revealed 33 studies providing pharmacokinetic and/or effectiveness 
data for 23% (16/70) of medications, 44% of which have just one study and can be 
considered exploratory. This work appraising 4 decades of literature shows several 
promising approaches: greater use of pharmacokinetic models applied to prospective 
clinical studies, dosing recommendations derived from both pharmacokinetics and 
safety, and multi-year effectiveness data on drugs for chronic conditions (e.g., asthma). 
Most studies make dose recommendations, but are weakened by retrospective study 
design, small study populations, and no controls or historic controls. Dosing decisions 
continue to rely on extrapolating knowledge, including targeting systemic drug exposure 
typically achieved in adults. Optimal weight-based dosing strategies vary by drug and 
warrant prospective, controlled studies incorporating pharmacokinetics and modeling 
and simulation to complement clinical assessment. 
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Introduction  
 
Obesity is becoming a common, chronic metabolic disease, with BMI and obesity rates 
rising dramatically in recent decades (1). This pattern is evident among pediatric 
populations in the United States as well as in overweight and obesity trends 
internationally (2, 3). Among those residing in countries with developing economies, 
23% are in the overweight or obese category, according to country definitions of these 
terms relative to the reference population (4). Currently 18.5% of U.S. children and 
adolescents have obesity and 5.6% have severe obesity (BMI ³120% of the 95th 
percentile of BMI-for-age, or an absolute BMI ³35 kg/m2, according to the CDC) (5, 6).  
 
Obesity is a progressive disease associated with pathophysiological changes in multiple 
organ systems: respiratory, hepatic, renal, cardiometabolic (hypertension, 
atherosclerosis, dyslipidemia) and insulin resistance, even among children with 
metabolically healthy obesity (7, 8). When obesity continues into adulthood, there are 
long-term health complications, e.g., cardiovascular events, especially for individuals 
with severe obesity (9).  
 
Children with obesity may be prescribed medication at a higher rate than children 
without obesity, as suggested by self-reported medication use in a longitudinal cohort 
study in the UK (10). A similar association was found among adolescents in a Canadian 
epidemiology study (11). Indications may include the management of obesity 
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comorbidities, most notably respiratory conditions, as well as perioperative care for 
orthopedic procedures, adenotonsillectomy, cholecystectomy and metabolic surgery in 
older children and adolescents. Solmi et al (10) recognized that their study was 
underpowered to detect significant differences in usage of specific therapeutic agents. 
Grouping medications by therapeutic classification, they found a strong association for 
high usage in children with obesity of medications for endocrine, respiratory and central 
nervous system conditions.  
 
Despite the clinical need for medication, obesity has not been routinely examined as a 
subpopulation within pediatrics in most clinical drug development programs, as 
determined by a recent comprehensive review of FDA databases and drug labels (12). 
Consequently, there is insufficient evidence-based dosing guidance for prescribing 
drugs in children with overweight or obesity (13).  
 
A systematic review of drug dosing in pediatric obesity published in 2015 was limited to 
studies with pharmacokinetic data (14). A review such as the present work allows a 
comprehensive scope to reviewing and critiquing published literature on broad issues. 
The purpose of this review is to evaluate the extent to which published clinical studies 
on common pediatric medications inform the process of prescribing in children and 
adolescents with obesity.  
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Methods 
 
Data Sources and Management 
We began by identifying drugs in common use among hospitalized children and 
adolescents. Data collected in a retrospective cohort study were utilized (15). The 
Pediatric Health Information System (PHIS), the administrative database of a national 
pediatric network, was the source for drug exposure data among 54,549 patients cared 
for in 2011-2012 and discharged from 42 ICUs, excluding neonatal ICUs, of general 
children’s hospitals across the U.S. (15). Data captured as Clinical Transaction Codes 
were converted to National Drug Codes and recorded by harmonized terminology using 
standardized dictionary of drug names. 
Therapies were ranked by extent of exposure, or prevalence, expressed as a 
percentage of patients exposed to the drug at any time during a PICU stay. Table S1 
displays a ranked list of drugs with exposures of 14% or greater.  
 
In preparation for the literature review, we identified drugs with a prevalence of ≥5%, 
provided the drug attained this threshold exposure rate in at least 2 of the age 
categories: infants, children and adolescents. Where appropriate we extended below 
that threshold to include metformin and to consider related or interchangeable drugs in 
a category to allow for differences among hospital formularies. We excluded therapeutic 
agents with prevalence ≥5% if they are not commonly encountered outside of critical 
care (e.g., dopamine, epinephrine, glycopyrrolate, lidocaine, milrinone) or in the 
immediate peri-surgical period (e.g., neuromuscular blocking agents, propofol). Also 
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excluded were blood products, ocular products, parenteral fluids, electrolytes and 
parenteral nutrition. With these additions and exclusions, the medication list totaled 70 
for searching published literature. 
 
Search Strategy and Study Selection 
English language PubMed articles from January 1970 - November 2018 were searched 
using the search string shown in Figure 1. Drug names for the search were from the 
PICU list were also prevalent among general pediatric inpatients (16). The drugs 
consisted of 70 medications in 8 therapeutic categories: analgesics, antimicrobials, 
asthma/allergy/inflammation, cardiovascular, central nervous system, coagulation, 
diabetes and gastroenterology. We excluded reports on drugs used predominately in 
pediatric anesthesia or procedural sedation. 
 
Authors independently reviewed abstracts of articles identified by the search. For 
articles identified by this search, reference lists were examined for additional data 
sources that met our criteria. Additional articles not found in the original search were 
considered for inclusion. This aspect deviated from the strict criteria of a systematic 
review approach.  
 
Results were screened for inclusion of pediatric studies or case series of dosing 
strategies in association with efficacy or effectiveness measures, and/or 
pharmacokinetics. We included published pediatric studies in which the study 
population represented a spectrum of body sizes, provided outcome data were 
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presented separately for the group with overweight or obesity or where data were 
combined, the percentage of individuals with overweight or obesity was ≥20%. The 
literature search process is displayed in a flow diagram consistent with the PRISMA 
statement (17) (Figure 1).  
 
From each study included in this review, we collected patient population size, age, body 
size categories; drug dosing information; study design; outcomes and key findings that 
might impact dosing in obesity. 
 
Findings: An Overview 
 
The PubMed search initially returned 466 records (Figure 1), and most were eliminated 
after abstract review because they were not relevant. With 6 additional articles from 
manual searching, final results consisted of 33 studies. 
 
The published literature indicated substantial gaps in knowledge about drug dosing and 
response in childhood obesity. For 70 medications in common use among hospitalized 
pediatric patients, only 23% (16/70) of these drugs were specifically studied in pediatric 
patients with obesity (Table 1). Key study features extracted from the publications are 
displayed in Table S2: population, design, dosing, PK and other outcome data, were 
and. Also, the column “Possible Dosing Impact in Obesity? yes/no” suggests which 
Common Drugs Studied in Pediatric Patients with Obesity  
 
9 
findings, particularly if replicated in additional pediatric studies, would translate to 
needing dose modification in pediatric patients with obesity. 
 
Among the 33 investigations, many enrolled fewer than 40 pediatric patients. 
Exceptions were several retrospective antimicrobial pharmacokinetics studies and two 
effectiveness studies of asthma medications, one which retrospectively evaluated 103 
children with obesity taking inhaled budesonide and another retrospective study of 
inhaled beta-agonists evaluated 1066 pediatric patients with obesity. Where multiple 
studies existed on a given drug, heterogeneity precluded pooling for secondary 
analysis. Of the 16 drugs investigated, 7 drugs had only one study: albuterol, 
budesonide, cefazolin, fosphenytoin, metformin, tobramycin and warfarin. Findings from 
single studies can be considered exploratory, requiring confirmation in new clinical 
research studies, case series and/or registries. 
 
While most work was published in the past decade, some studies involved data 
collection over several years. As a result, some dosing schemes employed were no 
longer current at the time of data analysis, relative to product labeling, institutional 
practice protocols or published clinical practice guidelines.  
 
Of the publications identified by this review, 64% (21/33) of studies were conducted 
retrospectively. Analysis of previously obtained patient data was dominant among 
antibiotic and anticoagulant drug studies. This retrospective study design underscores 
the pragmatic approach to clinical research in pediatric subpopulations. 
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Antimicrobials collectively represented the most common therapeutic class with 
published data and vancomycin was the leading single drug studied in pediatric obesity. 
The next most commonly evaluated categories were anticoagulants and analgesics. 
Fewer investigations are published in the areas of anti-seizure drugs/sedatives, 
asthma/allergy/inflammation, diabetes and gastroenterology. We found no studies on 
common cardiovascular agents. 
 
Dosing was observed to be either a fixed dose or a dose based on weight or other 
measure of body size. Fixed dosing approaches included fixed-tiered by age category, 
fixed-tiered by weight or BMI category, or by both age and body habitus. 
In weight-based dosing, options were total body weight (TBW) or an adjusted measure 
such as lean body weight (LBW) or ideal body weight (IBW) (Table S2). 
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Findings and Discussion by Therapeutic Category 
 
Analgesics 
Acetaminophen. The single most frequently administered medication, acetaminophen 
was noted in at least half of patients (15). Despite broad utilization since it was first 
available by prescription in 1952 (18), few investigations studied the impact of obesity 
on acetaminophen metabolism, disposition, analgesic effect or toxicity in pediatric 
patients. 
 
The maximum single dose is 1,000 mg while the daily dose per the product label should 
not exceed 4,000 mg in both adults and children ≥50kg to avoid hepatotoxicity (19). 
Intravenous (IV) acetaminophen has a role in managing fever and postoperative pain, in 
order to minimize or avoid opiates. Hakim et al. (20) recruited 11 adolescent girls with 
severe obesity and administered a single 1,000 mg IV dose following bariatric surgery. 
Subsequent serum acetaminophen concentrations, <30 µmol/L (4.5 µg/mL), were 
inadequate for analgesia. Investigators advised targeting a concentration >66 µmol/L 
(10 µg/mL) within 2 h of an IV infusion. That level might be achieved through weight-
based dose incorporating some adjustment (e.g., allometric scaling), which would 
require more research to define. 
 
Barshop et al. (21) compared PK parameters in 12 boys with obesity and nonalcoholic 
fatty liver disease (NAFLD) to 12 age-matched boys without obesity and with normal 
liver function. Following a single 5 mg/kg oral dose not exceeding 325 mg, the 
glucuronide metabolite to acetaminophen ratio, was higher among children with obesity. 
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This finding, measured at just one timepoint, suggests enhanced drug conjugation in 
obesity. Single dose PK parameters, however, were similar between groups, providing 
no indication that dosing of acetaminophen should be different. Further investigation of 
acetaminophen’s metabolic clearance is warranted using multiple dosing in larger 
numbers of pediatric patients across a broad body size spectrum. 
 
Fentanyl. PK of fentanyl was evaluated in 6 adolescents with severe obesity 
(BMI>99th%) who received IV doses based on IBW in bariatric surgery (22). Clearance 
was higher, but volume of distribution (V) was not markedly different among these 
adolescents compared to adult historic controls. 
 
Time to attain individualized goal sedation after the start of an infusion was 
retrospectively evaluated in 18 patients with obesity and 56 patients without obesity 
(23). The time to goal sedation was highly variable, regardless of body weight, and only 
weakly associated with the initial infusion rate.  
 
Antimicrobial Agents  
Cefazolin. The β-lactams are the largest of the various antibiotic classes, yet only one 
has been studied in pediatric obesity. A weight-based IV dose of cefazolin was 
prospectively evaluated in 5 children with obesity in a PK study in Japan (24). Dosing 
weight was an average of TBW and IBW. PK parameters did not differ significantly in 
the children with obesity compared to historic controls, who were children of normal 
body weight. 
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Clindamycin. Grouped as one of the 32 understudied drugs lacking pediatric dosing 
advice and safety data, clindamycin was prospectively evaluated for effect of body 
habitus and age on dosing. As part of the Pharmacokinetics of Understudied Drugs 
Administered to Children Per Standard of Care trial program (25), PK data were 
combined with two other prospective studies (26) to develop a population 
pharmacokinetic (PopPK) model (27). Collectively, the publication encompassed 76 
children with obesity and 49 children with healthy body weight, who received 
clindamycin 20 to 40 mg/kg based on TBW, up to a maximum daily dose of 2,700 mg, 
which is at the upper end of the dosing range for adults. The PopPK model confirmed 
the validity of the practice of dosing clindamycin based on TBW, according to age-
based dosing recommendations. 
 
Aminoglycosides. Tobramycin and gentamicin are water soluble molecules known to 
distribute extensively into extracellular body water. Body fluid dynamics are altered with 
obesity and developmental age. Some water resides in adipose tissue, particularly 
extracellular fluid which increases with increasing weight. Consequently, changes in 
pharmacokinetics of drugs like aminoglycosides which distribute into extracellular body 
water are more evident in persons with severe obesity (28). 
 
For drugs with a narrow therapeutic index that are known to be highly water soluble, 
current dosing practice in obesity, in adults and children, is based on IBW plus a 
percentage of the excess body weight into which the water-soluble drug distributes. In 
the case of aminoglycosides, the adjusted dosing weight is equal to IBW + 0.4*(TBW – 
IBW), where 0.4 is a correction factor correlating with 40% of excess body weight (29). 
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The correction factor may vary for other drugs, according to available knowledge about 
their partitioning and distribution. IBW is estimated by one of several available equations 
that utilize readily measurable patient characteristics, i.e., height and sex. 
 
Koshida et al. (24) administered one dose of IV tobramycin to the same Japanese 
children as in the cefazolin study utilizing an adjusted dosing weight, i.e., an average of 
TBW and IBW, in recognition of the distribution characteristics of the aminoglycoside. 
As expected, the predicted volume of distribution at steady state (Vss), expressed as 
liters per kg of TBW (L/kg), was smaller in children with obesity, whereas clearance was 
similar to pediatric historic controls. 
 
Choi et al. (30) evaluated gentamicin concentrations previously measured in 25 children 
with obesity and compared the values to control patients of healthy body weight, 
matched for age, sex and antibiotic indication. Although dosing was based on TBW, the 
individual dose was capped at 120 mg. Gentamicin Vss (L/kg of TBW) was smaller in 
the children with obesity, consistent with the tobramycin study. Peak concentrations 
were higher, and concentrations at the end of the 8 h dosing interval exceeded the 
advised limit of 4.2  µmol/L (2 mg/L) in 16% of patients with obesity but in no children of 
healthy body weight. The investigators noted that dosing is challenging due to 
interpatient variability in the amount of extracellular water contained in adipose tissue 
and the changing composition of body water and fat over the course of normal child 
development.  
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Options for dosing weight and measures of body composition to optimize attainment of 
therapeutic serum levels continue to be explored. Using modeling and simulation with 
gentamicin serum concentrations from over 500 pediatric patients across the body 
weight spectrum, Moffett et al. (31) predicted that an optimized body weight adjustment 
could be achieved using fat-free mass, as an alternative to IBW. Fat-free mass, which 
consists of bone, muscles, non-adipose components of organs, extracellular water and 
blood volume, approximates LBW minus lipid membranes (32). Fat-free mass can be 
estimated in the clinical environment using readily accessible patient measures, e.g. 
height and weight (33). 
 
Vancomycin. As one of the oldest approved prescription drugs, introduced in the U.S. 
in 1952, vancomycin is a mainstay treatment of life-threatening methicillin-resistant S. 
aureus infections.  
 
In adults, changes in V with excess body weight are inconsistent among published 
reports (29) whereas clearance increases as body weight increases. Both V and 
clearance are correlated with TBW rather than LBW in adults with severe obesity (34). 
TBW is therefore used for initial empiric dosing of vancomycin in adults (35). Dosing 
intervals may require shortening in patients with obesity and normal renal function to 
ensure serum vancomycin concentrations remain above the minimum inhibitory 
concentration (MIC) (36).  
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Therapeutic drug monitoring is common in patients with obesity to maintain drug 
concentrations within a defined range to ensure efficacy. Monitoring has been reported 
since the 1980s, including exploration of patient-level covariates for vancomycin levels 
i.e., age, creatinine clearance and body weight.  
 
A total of 8 studies, 7 retrospective and 1 prospective, published from 2011 - 2015 and 
involving over 300 pediatric patients with obesity, characterized the pharmacokinetics of 
vancomycin and/or described dosing practices in this pediatric subpopulation. By 
utilizing data from patients who were prescribed this antibiotic by their treating 
physicians according to institutional standards of care, the investigators took advantage 
of blood draws for serum concentration measurement, as part of routine medical care.  
 
Two vancomycin reports were PK analyses. In a study of 87 children with overweight or 
obesity and 87 children of healthy body weight matched for age and renal function, V 
was predicted best using TBW. Clearance was best described using TBW to the power 
of 0.75, also known as allometric weight (37). In another analysis of 115 children and 
adolescents over a wide spectrum of body sizes, Camaione and colleagues (38) 
speculated that defining a desired target range for area-under-the-concentration-time 
curve (AUC) might be worth exploring as an alternative to target drug concentrations, 
i.e., peak and trough. They also proposed body surface area (BSA) as an alternative to 
body weight. Implementing these options may not be feasible in resource-constrained 
institutions that cannot offer AUC-based vancomycin monitoring services (39). 
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The remaining 6 published reports were clinical studies. In the only prospective 
observational study, dosing vancomycin using a twice daily frequency resulted in 
vancomycin AUC to MIC ratios and trough concentrations considered clinically 
inadequate (mean trough, 2.3 µmol/L [3.4 mg/L]) regardless of body weight (40). In the 
other reports where the dosing interval was shorter, those with obesity were more likely 
to have somewhat higher mean trough concentrations compared to peers of healthy 
body weight. The magnitude of the values depended upon the vancomycin dosage 
regimen, generally ranging between 40 and 60 mg/kg daily in 3 or 4 divided doses (41, 
42, 43, 44, 45). It is noteworthy that when dose and dosing interval were stratified by 
both age and TBW, the mean trough concentrations were close to goal of >6.9 µmol/L 
(10 mg/L), i.e., 9.9 µmol/L (14.4 mg/L) in pediatric patients with obesity, and 7.2 µmol/L 
(10.5 mg/L) in those of healthy body weight (42). Thus, it may be optimal when both 
TBW and age are factored into vancomycin regimens, with younger children requiring 
higher body weight-based doses and shorter dosage intervals (42).
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Asthma, Allergy and Inflammation  
Albuterol. About one-quarter of new asthma cases in children with obesity can be 
ascribed directly to obesity, based on electronic U.S. health data (46). Furthermore, 
obesity is correlated with worse asthma-related outcomes and decreased bronchodilator 
responsiveness (47) among children who are Black or Latino . In a case-control, cross-
sectional analysis of nearly 3,000 patients from 2 retrospective studies (48), 36% had 
obesity (BMI ≥95th%). In this racial/ethnic minority population, the odds of being 
unresponsive to albuterol were 24% greater in individuals with obesity compared to 
children with lower BMI. The bronchodilator-unresponsive patients with obesity were 
less likely to have well-controlled asthma, despite increased usage of controller 
medication (i.e., leukotriene receptor inhibitor, inhaled corticosteroid with long-acting 
beta-2 agonist). 
 
Budesonide. In addition to being severe and poorly responsive to medications, obesity-
related asthma in children is likely nonallergic (49). Forno and colleagues (50) examined 
the relationship between BMI and responsiveness to inhaled glucocorticoids in a post-
hoc analysis of cases from a 4- to 6-y asthma trial. They found a decreased 
improvement in lung function with budesonide in children with obesity when compared 
to participants without obesity. Limited by the dose specified in the study protocol, the 
analysis could not inform whether higher doses might have been more efficacious in 
obesity.  
 
Central Nervous System 
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Fosphenytoin. Therapeutic drug monitoring is a common practice during antiepileptic 
therapy with phenytoin or its prodrug, fosphenytoin. Messinger et al. (51) retrospectively 
collected fosphenytoin dosage information and corresponding phenytoin concentrations 
in 110 children and adolescents across the body weight spectrum. After a mean IV 
TBW-based loading dose of 23 mg phenytoin equivalents/kg, the mean ± standard 
deviation plasma concentration at 2 to 4 h was 89 ± 27 µmol/L (22.4 ± 6.8 mg/L). In 
multivariable linear regression analysis, dose but not body weight, was a significant 
contributor to serum phenytoin concentrations. Additional drug therapy for control of 
seizures was not required more often in patients with high BMI. It was concluded that 
children with obesity and status epilepticus do not require higher mg/kg fosphenytoin IV 
loading doses.  
 
Midazolam. PK of midazolam was prospectively studied in 19 adolescents with obesity 
or overweight following a single IV dose of 2 or 3 mg (52). Findings supported a fixed 
dose since TBW was not predictive of clearance. Across the body weght spectrum of 62 
to 150 kg, higher TBW was associated with a larger V, which investigators attributed to 
excess body weight. A subsequent analysis combined data from these adolescents with 
data from a multicenter study of 20 adults with BMI >40 kg/m2 who received 5 mg IV 
(53). The combined data set provided an even broader body size distribution. Findings 
indicated that clearance in fact increased with higher TBW, and clearance among 
adolescents was higher than that in adults (54). 
 
Coagulation and Thrombosis 
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Enoxaparin – Prophylactic Dosing. Obesity is an independent risk factor for 
developing venous thromboembolism (VTE). For VTE prophylaxis in the general 
pediatric population, the American College of Chest Physician clinical practice 
guidelines specify dosing subcutaneous enoxaparin 0.5 mg/kg every 12 hours (55). The 
upper limit of dosing in pediatrics traditionally has been the adult dose (56), which is 
either 30 mg every 12 hours or 40 mg daily for enoxaparin.  
 
In a retrospective case series, Lewis and colleagues (57) reviewed hospitalizations of 3 
adolescent males with obesity or severe obesity initiated on enoxaparin 40 mg once 
daily for VTE prophylaxis. In all patients, both upward titration of the dose and 
shortening of the dosing interval to 12 hours was required to achieve the recommended 
target activated anti-factor X-activated (anti-Xa) range of 0.1 to 0.3 units/mL measured 4 
to 6 hours after a subcutaneous injection. Authors speculated that PK differences in 
adolescents with obesity was due to increased body-fat percentage or higher renal 
blood flow and increased glomerular filtration rate. Researchers concluded a reasonable 
approach in obesity would be to start with a fixed dose of a low molecular weight 
heparin in children >40 kg with monitoring of anti-factor Xa levels. 
 
Mushtaq et al. (58) investigated enoxaparin dosing in a prospective study of 4 
adolescents with severe obese (BMI >99th%) receiving perioperative VTE prophylaxis 
for bariatric surgery. Individuals with BMI <50 kg/m2 received 40 mg every 12 hours and 
BMI >50 kg/m2 received 60 mg every 12 hours, which resulted in anti-Xa in the target 
range, although the levels were lower than historic data from adults of normal BMI. 
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Authors concluded this two-tiered, body size-adjusted fixed dosing is adequate for 
thromboprophylaxis in adolescents with obesity. Further evidence to support that 
approach as a dosing recommendation was recently provided by a similar prospective 
study of enoxaparin prophylaxis with fixed doses of either 40 or 60 mg stratified by BMI 
<50 or ≥50 kg/m2, respectively. The BMI-stratified dosing achieved desired anti-Xa 
activity in 10 of the 12 (83%) adolescent bariatric surgery patients (59). 
 
Enoxaparin – Treatment Dosing. Two pediatric studies examined the effect of dose-
capping or reduced doses of enoxaparin for VTE treatment. In a retrospective review of 
30 pediatric patients, an average TBW-based dose of 0.8 mg/kg of enoxaparin was 
administered to children with obesity, with a maximum of 170 mg, compared to 1.1 
mg/kg in their case-control counterparts (60). Higher initial anti-Xa levels were observed 
in those with obesity but subsequent anti-Xa levels were in the therapeutic range and 
early dose adjustment did not appear necessary. Authors concluded no dosing 
adjustment is necessary in pediatric obesity but closer monitoring over time is warranted 
to avoid supratherapeutic levels and bleeding events.  
 
Reduced doses (≤1 mg/kg/dose every 12 h, the standard initial treatment dose) of 
enoxaparin were retrospectively examined as a possible approach to avoid 
supratherapeutic anti-Xa levels in 30 adolescents with overweight or obesity receiving 
the drug twice daily subcutaneously as treatment for VTE (61). TBW-based initial doses 
of 0.7 to ≤1 mg/kg were effective, although VTE progressed in 2 adolescents initially 
dosed below 0.7 mg/kg. During 3 months of treatment, 83% of anti-Xa levels were in the 
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desired range (0.5 to 1.0 units/mL). At the end of treatment, the mean dose, adjusted to 
target anti-Xa, was 0.8 mg/kg. Bleeding was similar between groups.  
 
Heparin. In a retrospective cohort study of 25 children with obesity, Taylor et al. (62) 
investigated the effect of weight on coagulation parameters and dosing requirements 
during a weight-based continuous infusion of heparin. Patients with obesity required 
significantly lower initial and maintenance infusion rates per kilogram compared to the 
25 age- and sex-matched children of healthy body weight. The mean ± standard 
deviation infusion rate was 19.1 ± 6.7 U/kg/h in patients with obesity compared to 24.3 ± 
9.6 U/kg/h in 25 patients without obesity (p= 0.033) to achieve stable therapeutic 
monitoring values. Authors hypothesized this difference was attributable to heparin’s 
less extensive distribution into adipose tissue compared to lean muscle. 
 
In contrast, in another retrospective review examining a single heparin bolus for 
prophylaxis prior to cardiac catheterization, Moffett et al. (63) found a similar response 
regardless of body weight with no need to adjust the dose in the 39 pediatric patients 
with obesity. This cohort study was limited in its use of only a single bolus dose and 
monitoring with the activated clotting time rather than with a more specific, sensitive 
monitoring test such as aPTT or anti-Xa activity. 
 
Warfarin. To determine whether obesity affects time to therapeutic INR, Moffett et al. 
(64) conducted a retrospective cohort evaluation of hospitalized pediatric patients 
initiated on warfarin therapy, following a standard institutional protocol for initial dosing 
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and subsequent titration. The institutional protocol included a maximum initial dose of 5 
mg to prevent overdose and did not accommodate exceptions for the presence of 
obesity. Time to achieve a therapeutic INR in the 10 patients with obesity was twice as 
long and more variable compared to 20 age- and sex-matched patients of healthy body 
weight: median [range] 6 [4 to 28 d] vs. 3 [1 to 10 d], p<0.01. Authors posit altered 
warfarin dosing requirements in obesity may be due to increased V and/or related to 
elevated triglycerides which correlate with elevated plasma vitamin K concentrations. 
Authors suggested that elimination of the dosing cap for patients with obesity may 
prevent the prolonged time to therapeutic INR observed in this study. 
 
Diabetes 
Metformin. Both metformin and basal insulin are FDA-approved for glycemic 
management in children and adolescents with type 2 diabetes (T2D) (65). As they age, 
children with T2D and obesity are likely to have increasingly severe obesity (66). 
Obesity management is not a labeled indication for metformin, but it is associated with 
modest weight reduction in children and weight stabilization in adolescents with obesity 
and insulin resistance (67, 68, 69). 
 
The effect of overweight and obesity on metformin PK was a pre-specified secondary 
objective of a randomized, triple-blind, placebo-controlled trial in youth with insulin 
resistance. The PK sub-study enrolled 17 adolescents with obesity and 5 adolescents 
with overweight (overall mean TBW, 79 kg; estimated LBW, 49 kg) (70, 71). In these 22 
outpatients, all of whom had normal renal and hepatic function, metformin clearance 
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was higher as weight increased. Transporter genes affecting metformin disposition were 
evaluated as covariates in the model but did not indicate a contribution from gene 
polymorphisms.  
 
Oral metformin clearance was higher in that study compared to a study in 4 pre-
adolescent girls who were not obese. It was hypothesized that excess body weight was 
associated with increased renal tubular secretion through induction of renal transporters 
(72).  
 
With clearance in children with obesity approaching that reported in adults of healthy 
body weight, the investigators proposed re-evaluation of the maximum dosage of 2,000 
mg in children with obesity if there is inadequate response. They propose using the 
maximum daily dose for adults with normal renal function, which is 2,550 mg per the 
FDA product label (73) and 3000 mg, per the Summary of Product Characteristics (74). 
The current clinical practice recommendation for children is to add insulin to metformin 
to achieve glycemic control rather than to exceed dosage limits described in the label 
(66). High doses are often accompanied by fatigue and gastrointestinal adverse effects, 
which are affected by the rate of up-titration of the metformin dosage. Additionally, 
children have low tolerability of tablet size and quantity and consequently incomplete 
medication adherence. These concerns are more prominent in young children (69). In 
general, tolerability and safety are important considerations when contemplating using 
maximum adult daily dosages to achieve adult-level systemic drug exposures in 
children with obesity.  
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Gastrointestinal Agents 
Pantoprazole. Proton pump inhibitors (PPIs) are acid suppressive drugs used in the 
treatment of gastroesophageal reflux disease (GERD), which is common in pediatric 
patients with obesity. Pantoprazole is the only PPI that has been studied in pediatric 
obesity. The traditional approach of PPI dosing involves empiric dose escalation for 
obese individuals given their higher TBW. 
 
Two prospective trials investigated the effect of body weight on pantoprazole PK in 
children and adolescents (75, 76). Individuals with higher BMIs exhibited higher 
systemic pantoprazole exposures and slower drug clearance compared to historic 
controls (76). Authors cautioned that TBW-based dosing in pediatric patients with 
obesity would likely generate a higher risk for long-term adverse events (e.g., 
osteopenia and fractures, mineral and vitamin deficiencies) without additional 
therapeutic benefit. In contrast, LBW dosing in children and adolescents with obesity 
achieved similar drug exposure to their counterparts of healthy weight. The study 
confirmed the variation in PK ascribed to age-related maturation of and genetic 
polymorphism in CYP2C19, the PPI’s primary metabolizing enzyme. Authors concluded 
dose escalation based on higher weight is not advisable. Dosing can be based on the 
same guidelines as healthy body weight peers of similar age and drug metabolizing 
capacity.  
 
An extended analysis of data from the original prospective study of 41 children and 
adolescents with GERD and obesity used simulation in a PopPK model to compare two-
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tiered fixed dosing to LBW- or TBW-based dosing strategy and concluded that fixed 
dosing strategy is suitable (77). A two-tiered strategy for children ≥5 yr is specified in the 
U.S. product label for delayed release pantoprazole: 20 mg once daily for weight 15 to 
<40 kg; 40 mg once daily for weight >40 kg (78). 
 
Research is needed to elucidate the mechanism by which obesity affects pantoprazole 
disposition and to determine whether the dosing approach for pantoprazole can be 
generalized to other PPIs. 
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General Critique and Points of Special Interest 
 
Our findings indicate that existing published studies on therapeutics in pediatric obesity 
are sparse and have not focused on some of the most prevalent agents used in 
hospitalized pediatric patients. When no pediatric information exists in the literature to 
inform drug use, clinicians and researchers often rely on expert opinion and evidence 
from adult populations (7). For PK data derived from adult obesity studies, extrapolation 
to pediatric patients has limitations. With midazolam, for example, findings in an 
adolescent PK study conflicted with a prior report in adult obesity (54).  
 
A premise for extrapolation is that the disease, its progression and response to 
intervention are sufficiently similar between adults and children to justify extrapolation 
for therapeutic decision making (79). It is not established, however, that obesity and its 
natural history are similar in adult and pediatric populations. Like type 2 diabetes across 
the age spectrum, there may be distinctions between juvenile onset and adult onset 
obesity (80, 81). Also, the underlying disease being treated may differ between age 
groups, as is the case for thrombotic disease and obesity-associated asthma in 
adolescents compared to adults (49, 61). 
 
The studies presented here underscore practical challenges in undertaking clinical 
studies in pediatric subpopulations, i.e., ethics, feasibility and availability of resources to 
conduct robust clinical research. Utilizing real world data is acknowledged as an 
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acceptable pragmatic strategy for pediatric therapeutic research, particularly for PK and 
PD studies (82). 
 
Most studies identified in this review were conducted retrospectively at a single center, 
involved small numbers of pediatric patients with obesity, and relied upon administrative 
databases to capture of information. These aspects can introduce informational bias, 
bias due to misclassification of obesity status, and selection bias. Combining data from 
multiple studies, as was done with midazolam for adults and adolescents (54), albuterol 
for children and adolescents  up to the age of 21 y (47) and clindamycin (27), addresses 
the issue of adequate numbers to help ensure generalizability, however, pooling may 
introduce additional variability. Given the limitations imposed by study design and study 
conduct, as described in published drug studies in pediatric obesity, translation of their 
findings to the clinic should only be done with careful patient monitoring.  
 
Despite their limitations, retrospective studies are useful in generating hypotheses for 
testing in subsequent prospective trials. An alternate strategy is to prospectively 
consent parents on behalf of young patients who are, or would soon be, prescribed a 
medication for biological sample collection on the same schedule as clinical care 
samples (27, 40, 83). A third approach is to intensify use of existing clinical research 
resources designed for adults (84). Specifically, including older adolescents with obesity 
into clinical studies of adults across a body weight spectrum may be considered. 
National Institutes of Health clinical research funding in fact now carries the expectation 
of inclusion of children and adolescents, allowing for exceptions for ethical reasons or 
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with scientific justification (85). With the high overall prevalence of overweight and 
obesity in both genders [23.8% (22.9 to 24.7) of boys and 22.6% (21.7 to 23.6) of girls 
residing in countries with developed economies (4)], it may be feasible to extend clinical 
research to include this subpopulation in multinational clinical research. The aim is to 
efficiently acquire knowledge about efficacy or effectiveness, safety and/or drug 
disposition in children and adolescents in advance of designing and conducting 
dedicated drug trials in pediatric patients with obesity, if they are considered necessary. 
 
A strength of our review is its broad coverage of 70 common pediatric medications, 
based on a cross-section of 42 U.S. pediatric medical centers encompassing tens of 
thousands of patient admissions. We believe this approach to the question of the effect 
of obesity on drug dosing would identify medications likely to be relevant to general 
hospital practice. Prior pediatric reviews narrowed their coverage by focusing on one 
therapeutic category, e.g., antimicrobials (86), area of practice, e.g., surgery (87) or 
emergency medicine (88), or PK properties of drugs (14). The later major review yielded 
mostly uncommon drugs. Of the studies we report, over 70% were published after the 
completion of their literature review phase in 2012. Another review reported on 23 
common inpatient drugs but offered little description and critique of the study designs 
(89). 
 
A few observations about our work are noted with respect to its scope and process. The 
range of identified drugs was specifically those in use among U.S. pediatric intensive 
care patients in 2011 - 2012. While the types of medicine in common use in the acute 
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care setting differ only slightly between countries (90), drugs licensed since 2012 are 
not represented in our literature review. Since then, the armamentarium expanded, but 
drug utilization patterns tend to be consistent over time as prescribers use drugs with 
which there is known clinical experience. We evaluated medications prescribed in 
pediatric hospital practice, which omitted some drugs prescribed more often in settings 
outside of acute care (91). The inpatient drugs on which our literature search was based 
did not encompass several drug categories frequently prescribed to US pediatric 
outpatients. Categories include medications for depression (sertraline, fluoxetine), 
attention-deficit/hyperactivity disorder (ADHD) and contraception (89, 92). Finally, our 
literature search was limited to one database, PubMed, albeit over a span of many 
decades.  
 
Concluding Statement  
Healthcare providers regard obesity as a disease to be taken as seriously as diabetes, 
heart failure and hypertension (93), yet gaps exist in clinical obesity research for all 
therapeutic areas of medications in common use in pediatrics. Optimal dosing strategies 
vary by drug and are not necessarily generalizable even among chemically similar 
entities. Extrapolation from adult data has limitations. 
 
Despite recent progress in pediatric clinical drug research (94), researchers, drug 
developers and clinicians should strive to develop high-quality evidence on which to 
base dosing decisions. Prioritization is warranted for drugs that are extensively used 
(e.g., acetaminophen), used on a regular daily basis (e.g., medication for ADHD, oral 
contraceptives), important for management of obesity co-morbidities (e.g., statins, 
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respiratory medicines), associated with weight gain during long-term use (e.g., 
antidepressants and antipsychotics, steroids), expensive (e.g., factor product, 
recombinant biologics), or characterized by a narrow therapeutic index. 
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Table Legends  
 
Table 1.  
Presence of Published Pediatric Obesity Studies of 70 Commonly Used Medications in 
Children and Adolescents 
 
Supplemental Tables 
Table S1. 
Common Drug Exposures (14% or higher) Among Patients in PICUs at US Children's 
Hospitals 
 
Table S2.  
Common Drugs Evaluated in Children and Adolescents with Obesity: Evidence Tables 
from 33 Studies 
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Figure Title and Caption  
 
Figure 1. PRISMA Diagram 
Search string and flowchart of search process, identification and screening of studies for 
inclusion in the review. PRISMA indicates Preferred Reporting Items for Systematic 
Reviews and Meta-Analyses. 
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Figure 1 
English language PubMed articles from January 1970 through November 2018 were searched using the 
following search string: 
(((obesity[Title/Abstract] OR obese[Title/Abstract] OR overweight[Title/Abstract] AND 
(pharmacokinetics[Title/Abstract] OR pharmacodynamics[Title/Abstract] OR PK[Title/Abstract] OR 
PD[Title/Abstract] OR PK/PD[Title/Abstract] OR (medication[Title/Abstract] OR dosing[Title/Abstract])) 
AND (“infant”[MeSH Terms] OR “child”[MeSH Terms] OR “adolescent”[MeSH Terms])) OR 
((“pharmacokinetics”[Subheading] OR “pharmacokinetics”[All Fields] OR “pharmacokinetics”[MeSH 
Terms]) AND (“obesity”[MeSH Terms] OR “obesity”[All Fields]) AND (“infant”[MeSH Terms] OR 
(“infant”[MeSH Terms] OR “child”[MeSH Terms] OR “adolescent”[MeSH Terms])))) AND (“drug 
name”[MeSH Terms] OR “drug name”[All Fields]) 
 
 
466 Records identified through 
predefined search criteria
6 Additional records identified  
through manual searching
472    Records screened 
439  Records excluded 
 Reasons: 
 No exogenous drug exposure 
 No data on pharmacokinetic, drug  
  concentration or pharmacologic effect 
 No children included 
 No obese children 
 Not a drug of interest 
33 Studies included in analysis 
Table 1. Presence of Published Pediatric Obesity Studies Among 70 Commonly 
Used Medications in Children and Adolescentsa  
Therapeutic Category 
 
Drug Class 
Drug Name 
 
Study of 
Pediatric 
Obesityb 
 
 
ANALGESIC: 
   
    Non-Opiate  acetaminophen 
 
ibuprofen   
ketorolac   
aspirin   
    Opiate fentanyl 
 
morphine  
hydromorphone   
methadone   
oxycodone   
 
ANTIMICROBIAL:  
    Glycopeptide vancomycin 
 
    Cephalosporin cefazolin 
 
ceftriaxone   
cefotaxime   
cefipime   
ceftazidime   
cefuroxime   
    Penicillin piperacillin/tazobactam   
ampicillin ±sulbactam   
oxacillin   
    Lincosamide clindamycin 
 
    Macrolide azithromycin   
erythromycin   
    Carbapenem meropenem   
    Aminoglycoside gentamicin 
 
tobramycin 
 
    Sulfonamide trimethoprim/  
sulfamethoxazole   
 
ASTHMA, ALLERGY &  
INFLAMMATION:  
    Glucocorticoid dexamethasone   
methylprednisolone   
hydrocortisone   
budesonide 
 
prednisone   
    Antihistamine diphenhydramine 
cetirizine   
    Beta-Agonist albuterol 
 
 
CARDIOVASCULAR:  
    Diuretic furosemide   
chlorothiazide   
spironolactone   
bumetanide   
    ACE Inhibitor enalapril   
captopril   
    Calcium Channel Blocker nicardipine   
amlodipine   
    Beta Blocker metoprolol   
propranolol   
  labetalol   
 
CENTRAL NERVOUS SYSTEM:  
    Anti-epileptic lorazepam   
levetiracetam   
diazepam   
phenobarbital   
fosphenytoin or 
phenytoin 
 
clonazepam   
topiramate 
 
gabapentin   
oxcarbazepine   
    Sedative clonidine   
  midazolam 
 
  
 
COAGULATION: 
  
    Anticoagulant heparin 
 
enoxaparin 
 
warfarin 
 
    Antifibrinolytic aminocaproic acid   
tranexamic acid   
 
DIABETES: 
 
    Biguanide metformin  
    Hormone insulin  
 
GASTROINTESTINAL: 
 
    H2 Antagonist   ranitidine   
famotidine   
    Proton Pump Inhibitor pantoprazole 
 
omeprazole   
esomeprazole   
    Motility metoclopramide   
    5HT3 Antagonist ondansetron  
 
aBased on drug exposures, accumulated from 42 United States pediatric intensive care 
units, for patients ranging in age from 1 through 17 years. See text for details. 
 
bCheckmark indicates one or more published reports. 
 
